Table 4.
Case | Age | Sex | PS | Histology | Prior Therapy | Post Therapy | Volume of Effusion (mL) | Duration of Drainage (Days) | Number of Intrapericardial Doses of CBDCA Administered | Discharge from Hospital | Response | Survival after Intrapericardial Infusion (Days) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 76 | M | 4 | SQ | None | None | 1235 | 15 | 1 | No | NE | 10 |
2 | 64 | M | 3 | SCLC | CBDCA + VP-16 → CBDCA + CPT-11 | None | 3510 | 15 | 2 | No | NE | 11 |
3 | 69 | M | 3 | Large | None | VNR | 1720 | 10 | 1 | Yes | CR | 150 |
4 | 55 | F | 2 | AD | CDDP + GEM → CBDCA + PTX → DTX → GEF | GEF | 550 | 8 | 1 | Yes | CR | 110 |
5 | 64 | M | 3 | AD | None | CBDCA + PTX → DTX → GEF | 900 | 7 | 1 | Yes | CR | 313 |
6 | 48 | F | 3 | AD | DTX + GEM → GEF | None | 350 | 4 | 1 | Yes | PR | 188 |
7 | 70 | M | 3 | AD | CBDCA + PTX→ DTX + S1 | None | 1200 | 3 | 1 | Yes | Failure | 46 |
8 | 42 | M | 2 | SCLC | CBDCA + VP-16 + TRT → CBDCA + CPT-11 | None | 860 | 8 | 2 | No | CR | 31 |
9 | 63 | M | 2 | SCLC | CBDCA + VP-16 + TRT → AMR → CBDCA + CPT-11 | None | 1400 | 4 | 1 | No | NE | 20 |
10 | 63 | M | 3 | AD | CBDCA + PTX → DTX | None | 450 | 5 | 1 | Yes | CR | 145 |
11 | 67 | F | 2 | AD | CDDP + S1 + Bev → TRT → CRZ | PEM → ALC | 540 | 3 | 1 | Yes | PR | 2435 a |
12 | 51 | M | 3 | SQ | CBDCA + PTX + TRT → DTX → S1 → ERL → GEM | None | 3160 | 7 | 1 | Yes | CR | 53 |
13 | 50 | F | 3 | AD | CBDCA + DTX + Bev → PEM → ERL | None | 640 | 4 | 1 | Yes | CR | 99 |
14 | 44 | M | 2 | AD | CBDCA + PTX + TRT → CDDP + VNR | None | 11,380 | 85 | 3 | No | Failure | 66 |
15 | 59 | F | 3 | AD | None | CBDCA + PTX | 450 | 10 | 1 | Yes | CR | 69 |
16 | 59 | F | 3 | AD | CBDCA + DTX + Bev | DTX | 1285 | 10 | 1 | Yes | CR | 158 |
17 | 60 | F | 2 | AD | None | CBDCA + PTX → PEM | 1450 | 9 | 1 | No | CR | 71 |
18 | 58 | M | 3 | AD | CDDP + S1 → DTX | None | 1555 | 9 | 1 | No | NE | 24 |
19 | 46 | M | 2 | AD | None | None | 1270 | 14 | 1 | No | NE | 27 |
20 | 67 | M | 1 | SQ | CBDCA + PTX + TRT | None | 880 | 9 | 1 | Yes | PR | 136 |
21 | 69 | M | 3 | SQ | CBDCA + PTX | None | 2050 | 11 | 1 | Yes | CR | 245 |
a Alive at cut-off date. Abbreviations: PS, performance status; SQ, squamous cell carcinoma; SCLC, small cell lung cancer; Large, large cell carcinoma; AD, adenocarcinoma; CBDCA, carboplatin; VP-16, etoposide; CPT-11, irinotecan; CDDP, cisplatin; GEM, gemcitabine; PTX, paclitaxel; DTX, docetaxel; GEF, gefitinib; TRT, thoracic radiotherapy; AMR, amrubicin; Bev, bevacizumab; CRZ, crizotinib; ERL, erlotinib; PEM, pemetrexed; VNR, vinorelbine; ALC, alectinib; NE, not evaluated; CR, complete response; PR, partial response.